GH Stock Forecast & Price Target

Guardant Health is viewed favorably because it combines market leadership in liquid biopsy with multiple underpenetrated growth engines, including Guardant360, Reveal, and Shield, each expanding through stronger guideline support, broader reimbursement, and new clinical use cases. Its fundamentals are further strengthened by tangible operating momentum, with Q1'26 revenue of $302M, +48% Y/Y growth, 86k oncology tests, +47% Y/Y volume growth, 65% GAAP gross margin, and $1.2B of cash, while 2026 guidance was raised to $1.30-1.32B. The outlook is also supported by major de-risking catalysts such as UnitedHealthcare coverage for Shield effective August 1, 2026, ACS and NCCN guideline inclusion, and pricing/reimbursement upside that could expand ASPs and margins over time.

Guardant Health is facing a difficult competitive backdrop across therapy selection, MRD, and early detection, with large established labs and other precision oncology peers pressuring pricing and commercialization. Its core Guardant360 franchise still drives more than 60% of sales, so any slowdown from recent 30% year-over-year volume growth could quickly damage sentiment, while Shield’s market potential remains uncertain amid debated performance trade-offs and unclear USPSTF support. Cash burn above $200 million in each of the past two years, rising in the most recent quarter, and a crowded MRD launch environment increase balance-sheet and execution risk even as management targets breakeven by Q4 2027.